<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02012504</url>
  </required_header>
  <id_info>
    <org_study_id>B2012-127</org_study_id>
    <nct_id>NCT02012504</nct_id>
  </id_info>
  <brief_title>Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients</brief_title>
  <official_title>Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Who Meet Comorbidity of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the improvement of antidepressant monotherapy on
      depressive and anxiety symptom in Chinese patients who meet Diagnostic and Statistical Manual
      of Mental Disorders, Fifth Edition (DSM-5) criteria for the comorbidity of major depressive
      disorder (MDD) and generalized anxiety disorder (GAD)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the improvement of the quality of life of antidepressant monotherapy on Chinese
      patients who meet DSM-5 criteria for the comorbidity of MDD and GAD. To monitor adverse
      events (AEs) and serious adverse events (SAEs) of antidepressant monotherapy
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the score of HAMD17 (Hamilton Depression Rating Scale) and HAMA (Hamilton Anxiety Rating Scale) of patients in each time between two groups</measure>
    <time_frame>one year</time_frame>
    <description>The efficacy variables is include:
Onset rate: proportion of patient with at least 20% reduction in HAMD total score after 1 week Response rate: proportion of patient with at least 50% reduction in HAMD total score Remission rate: remission is defined as HAMD ≤ 7; remission rate is proportion of patients with remission HAMD total score change from baseline to week 6 and to week 24 (LOCF) during the study.
HAMA and the Mos36-item Short Form Health Survey (SF-36) score Change from baseline to week6 and to week 24 (LOCF) during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the symptom of depression, anxiety and quality of life in each time between two groups</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Adverse Drug Reaction</condition>
  <condition>Anxiety Disorders and Symptoms</condition>
  <arm_group>
    <arm_group_label>Western medicine</arm_group_label>
    <description>venlafaxine or escitalopram</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chinese medcine</arm_group_label>
    <description>Shuganjieyu capsule</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients who meet DSM-5 criteria for the combidity of MDD and GAD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First episode outpatients in department of psychiatry, aged 18-65 years

          2. Comorbidity of MDD and GAD according to DSM-5 criteria Hamilton Depression score
             (HAMD) of ≥18 at screening

          3. HAMA≥14 at screening

          4. Medically stable

          5. Provision of written, informed consent.

        Exclusion Criteria:

          1. Suicide ideation

          2. Use antidepressants within at least 14 days before study begin

          3. Substance or alcohol dependence at enrolment (except dependence in full remission, and
             except for caffeine or nicotine dependence)

          4. Opiates, amphetamine, barbiturate, cocaine, cannabis, or hallucinogen abuse within 4
             weeks prior to enrolment

          5. Unstable or inadequately treated medical illness (e.g. congestive heart failure,
             angina pectoris, hypertension, renal or hepatic dysfunction, cerebrovascular disease )
             as judged by the investigator

          6. Women in pregnancy or lactation

          7. Medical conditions that would affect absorption, distribution, metabolism or excretion
             of study treatment.

          8. Medical history with seizure disorder, except for febrile convulsion

          9. Participation in another clinical study within 4 weeks (or longer time according to
             the local requirement)

         10. Receive Electroconvulsive therapy (ECT) before study begin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian l Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao Huang</last_name>
    <phone>+862164041990</phone>
    <phone_ext>3012</phone_ext>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao Huang</last_name>
      <phone>+862164041990</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2013</study_first_posted>
  <last_update_submitted>December 10, 2013</last_update_submitted>
  <last_update_submitted_qc>December 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

